Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

IRLAB Therapeutics

1,64 SEK

+0,98 %

Mindre end 1K følgere

IRLAB A

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Dividend
Investorkonsensus
Sammenligne
+0,98 %
-3,29 %
-16,55 %
-28,52 %
-40,43 %
-87,56 %
-82,59 %
-95,21 %
-84,98 %

IRLAB Therapeutics is a Swedish research and pharmaceutical company. The research is based on the company's own research platform and specializes in the treatment of brain diseases, commonly referred to as neurodegenerative diseases. At the present, the company holds drug candidates specializing in, among other things, Parkinson's disease. The head office is located in Gothenburg.

Læs mere
Markedsværdi
139,64 mio. SEK
Aktieomsætning
12,89 t SEK
Omsætning
57,46 mio.
EBIT %
-162,54 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
6.5
2026

Delårsrapport Q1'26

20.5
2026

Generalforsamling '26

26.8
2026

Delårsrapport Q2'26

Alle
Selskabspræsentationer
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Pressemeddelelse2.3.2026, 07.45

IRLAB participates in Life Science Day in Gothenburg on March 4, 2026

IRLAB Therapeutics
Pressemeddelelse27.2.2026, 13.29

Redeye: IRLAB (Q4 Review): IRL757 study on track

IRLAB Therapeutics
Selskabsmeddelelse26.2.2026, 10.58

IRLAB secures milestone payment for first patient dosed in Phase Ib study with IRL757 in Parkinson’s Disease

IRLAB Therapeutics

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse25.2.2026, 06.00

IRLAB publishes full-year report for the period January – December 2025

IRLAB Therapeutics
Pressemeddelelse20.2.2026, 06.00

IRLAB has received scientific advisory board confirmation on next steps for pirepemat

IRLAB Therapeutics
Pressemeddelelse18.2.2026, 06.00

IRLAB: Invitation to the year-end report 2025 presentation and webcast

IRLAB Therapeutics
Pressemeddelelse19.1.2026, 10.40

IRLAB enters collaboration agreement with Danish biotech company Biomia ApS applying the Integrative Screening Process (ISP)

IRLAB Therapeutics
Pressemeddelelse23.12.2025, 06.00

IRLAB Receives Approval for a Phase Ib Study with IRL757 in Parkinson’s Disease

IRLAB Therapeutics
Pressemeddelelse11.12.2025, 06.00

The European Patent Office intends to grant a new patent for IRLAB’s mesdopetam.

IRLAB Therapeutics
Pressemeddelelse27.11.2025, 06.00

IRLAB participates in Redeye Technology & Life Science Day on December 3, 2025

IRLAB Therapeutics
Selskabsmeddelelse20.11.2025, 15.40

Nomination committee appointed for IRLAB’s annual general meeting 2026

IRLAB Therapeutics
Pressemeddelelse7.11.2025, 06.00

IRLAB receives acceptance for two abstracts at AD/PD™ 2026: The 20th International Conference on Alzheimer’s and Parkinson’s Diseases

IRLAB Therapeutics
Pressemeddelelse4.11.2025, 12.51

Redeye: IRLAB Therapeutics (Q3 review) - Approaching study initiation

IRLAB Therapeutics
Selskabsmeddelelse29.10.2025, 06.00

IRLAB publishes interim report for the period January - September 2025

IRLAB Therapeutics
Pressemeddelelse23.10.2025, 05.00

IRLAB: Invitation to the interim report for Q3 2025 presentation and webcast

IRLAB Therapeutics
Selskabsmeddelelse9.10.2025, 15.15

IRLAB appoints Gustaf Albèrt as the new Chief Financial Officer.

IRLAB Therapeutics
Pressemeddelelse9.10.2025, 05.00

IRLAB to present at Redeye Theme: Neurology

IRLAB Therapeutics
Pressemeddelelse2.10.2025, 05.00

IRLAB progresses fully funded IRL757 study in Parkinson’s Disease in partnership with MSRD

IRLAB Therapeutics
Pressemeddelelse4.9.2025, 05.00

IRLAB is granted a patent strengthening the market exclusivity of the drug candidate mesdopetam in China

IRLAB Therapeutics
Pressemeddelelse1.9.2025, 09.13

Redeye: IRLAB Therapeutics Q2 - Focus on value creation following strengthened financials

IRLAB Therapeutics
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.